BioXcel Therapeutics Inc. (NASDAQ:BTAI) went down by -4.06% during the previous trading session, and it is maintaining the win ahead of Friday’s trading session. The share price of the Biotechnology giant went up by $55.60 to trade ended Friday trading at $57.95. This is down from the $57.95 price recorded on Thursday’s trading session. Thanks to this latest performance, BTAI is closer to the higher price 52-week target of $150.00 and further from the lowest price target of $53.00. Its performance from the start of the year has also been positive, with BTAI up by 280.56% year-to-date.
BioXcel Therapeutics Inc. (BTAI) started the day trading at $57.67 and recorded an intraday high of $58.27. It also recorded an intraday low of $55.05 during Friday’s trading session. BioXcel Therapeutics Inc. is a very active stock that recorded a trading volume that is more than 52.35% of the average daily trading volume on Friday. The stock’s trading volume on Friday was 953466, which is more than 52.35 of the total average daily trading volume of 454.30K.
BioXcel Therapeutics Inc. (NASDAQ:BTAI) 2020 Performance Impressive
The increase in BTAI’s stock price on Friday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of BTAI currently stands at $61.50, which is higher than the current trading price of the stock by 9.59%. However, BTAI’s current trading price is -1378.72% lower than the 52-week low price of $3.76. In terms of trading volume, BioXcel Therapeutics Inc. currently experienced healthy participation during the last trading session. 953466 shares of BioXcel Therapeutics Inc. were traded on the stock exchange on Friday, which is more than 52.35% of the 454.30K average trading volume of the stock.
The performance of the stock has been positive over the past year. BTAI’s performance over the past one year has seen it surge by 407.30%, while the stock has gone up by 458.23% in the last six months. The quarterly performance of BTAI currently stands at 127.59%, and it is up by 29.30% in the last month. The only positive figure was from the weekly performance, which currently reads 5.60%. At the time of writing BTAI’s report, the company has a total market cap of $1.17B, making it one of the largest publicly-traded companies in the world.BioXcel Therapeutics Inc. also has over 27 employees all over the world.
BTAI Insider Activities
For BioXcel Therapeutics Inc., insiders hold 34.90% of all company shares. The insider transactions over the past six months are up by 1.80%. During that period, insiders bought 80,000 shares in 1 transactions. In that same period, insiders sold 600,000 of their shares in 2 transactions. After these transactions, insiders at BioXcel Therapeutics Inc. now hold 9.8M shares, which is over 28.52% of the total company stocks. Institutional investors currently hold a large chunk of the BTAI shares, as they control 48.51% of the company’s total stock.
BTAI Fundamental Analysis
For BioXcel Therapeutics Inc., the stock’s diluted earnings per share (EPS) stands at -2.36. In the coming year, analysts expect the EPS to be -3.00.
BTAI Analysts Prediction
Another analyst that has a Buy rating for BTAI is H.C. Wainwright, which set a price target of between $30 and $95. H.C. Wainwright reiterate their Buy position on the stock ($25 and $30)
BTAI Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of BTAI currently stands at 8.61%, while the SMA50 is 26.68%. The biggest one is the SMA200, which is currently reading 156.15% ahead of Friday’s trading session. The Relative Strength Index of this stock is 60.02.
